Clinical trials: Stage I Skin Cancer
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT01409811
- Testing
- zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer
RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the laboratory may help doctors learn how fluvastatin effects biomarkers related to breast cancer.
- Trial name
- NCT00416403
- Testing
- fluvastatin sodium, Breast Cancer Surgery Only - Arm III
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Menopausal Symptoms
Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer
RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early…
- Trial name
- NCT00003771
- Testing
- therapeutic estradiol, norethindrone acetate
- Where
- 6 sites in Finland, Norway and 3 more
- Volunteers
- 1,300 people
- Sponsor
- Regional Oncologic Center
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Breast Neoplasms
Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2
We, the researchers at Hamilton Health Sciences, have developed a novel approach to cancer therapy using transfected dendritic cells (DCs) to generate enhanced immunity to defined tumor antigens.
- Trial name
- NCT00197522
- Testing
- CD34+ derived DCs
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Hamilton Health Sciences Corporation
Cancer Survivor, Early-Stage Breast Carcinoma
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)
This randomized phase III trial studies how well mindfulness meditation or survivorship education work in improving behavioral symptoms in younger stage 0-III breast cancer survivors.
- Conditions
- Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer
- Trial name
- PTW (NCT03025139)
- Testing
- Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002837
- Testing
- Filgrastim (G-CSF), Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given to patients with metastatic melanoma. Researchers want to find out if TPI 287 can control the disease.
- Trial name
- NCT01340729
- Testing
- TPI 287
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network